Amid crowded migraine market, Lundbeck goes its own wayThe market for migraine treatment and prevention has been transformed by the launch of several new drugs targeting Share XAmid crowded migraine market, Lundbeck goes its own wayhttps://pharmaphorum.com/news/amid-crowded-migraine-market-lundbeck-goes-its-own-way/
FDA approves ‘potential blockbuster’ migraine jab from LundbeckThe FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs Share XFDA approves ‘potential blockbuster’ migraine jab from Lundbeckhttps://pharmaphorum.com/news/fda-approves-potential-blockbuster-migraine-jab-from-lundbeck/
